C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.005 AUD -3.37% Market Closed
Market Cap: 111.7m AUD

Wall Street
Price Targets

CYC Price Targets Summary
Cyclopharm Ltd

Wall Street analysts forecast CYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYC is 2.244 AUD with a low forecast of 2.222 AUD and a high forecast of 2.31 AUD.

Lowest
Price Target
2.222 AUD
121% Upside
Average
Price Target
2.244 AUD
123% Upside
Highest
Price Target
2.31 AUD
130% Upside
Cyclopharm Ltd Competitors:
Price Targets
NMTC
Neuroone Medical Technologies Corp
100% Upside
AFX
Carl Zeiss Meditec AG
27% Upside
MYO
Myomo Inc
322% Upside
BIM
Biomerieux SA
6% Upside
EUZ
Eckert & Ziegler Strahlen und Medizintechnik AG
6% Upside
SHL
Siemens Healthineers AG
31% Upside
MEDX
Medmix Ltd
53% Upside
ZBH
Zimmer Biomet Holdings Inc
15% Upside

Revenue
Forecast

Revenue Estimate
Cyclopharm Ltd

For the last 8 years the compound annual growth rate for Cyclopharm Ltd's revenue is 8%. The projected CAGR for the next 3 years is 50%.

8%
Past Growth
50%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Cyclopharm Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Cyclopharm Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYC's stock price target?
Price Target
2.244 AUD

According to Wall Street analysts, the average 1-year price target for CYC is 2.244 AUD with a low forecast of 2.222 AUD and a high forecast of 2.31 AUD.

What is Cyclopharm Ltd's Revenue forecast?
Projected CAGR
50%

For the last 8 years the compound annual growth rate for Cyclopharm Ltd's revenue is 8%. The projected CAGR for the next 3 years is 50%.

Back to Top